Philip J Stephens
Overview
Explore the profile of Philip J Stephens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
19581
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chung C, Li J, Steuer C, Bhateja P, Johnson M, Masannat J, et al.
Clin Cancer Res
. 2022 Mar;
28(11):2329-2338.
PMID: 35344035
Purpose: A phase II multi-institutional clinical trial was conducted to determine overall survival (OS) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with...
2.
Chudnovsky Y, Kumar R, Schrock A, Connelly C, Gowen K, Frampton G, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-9.
PMID: 35172500
No abstract available.
3.
Ou S, Cui J, Schrock A, Goldberg M, Zhu V, Albacker L, et al.
Lung Cancer
. 2019 Aug;
138:141.
PMID: 31447233
No abstract available.
4.
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick J, Kato S, Okamura R, Schwaederle M, Hahn M, Williams C, et al.
Nat Med
. 2019 Apr;
25(5):744-750.
PMID: 31011206
Cancer treatments have evolved from indiscriminate cytotoxic agents to selective genome- and immune-targeted drugs that have transformed the outcomes of some malignancies. Tumor complexity and heterogeneity suggest that the 'precision...
5.
Goldberg M, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, et al.
PLoS One
. 2018 Nov;
13(11):e0208097.
PMID: 30481207
After sequential treatment with first- and third-generation EGFR tyrosine kinase inhibitors (TKIs), EGFR-mutant non-small cell lung cancers frequently harbor multiple resistance mutations in exon 20 of EGFR including T790M, mediating...
6.
Zhou C, Yuan Z, Ma W, Qi L, Mahavongtrakul A, Li Y, et al.
J Hematol Oncol
. 2018 Nov;
11(1):129.
PMID: 30400986
Background: This retrospective study was undertaken to determine if the plasma circulating tumor DNA (ctDNA) level and tumor biological features in patients with advanced solid tumors affected the detection of...
7.
Schrock A, Welsh A, Chung J, Pavlick D, Bernicker E, Creelan B, et al.
J Thorac Oncol
. 2018 Oct;
14(2):255-264.
PMID: 30368012
Introduction: Genomic profiling informs selection of matched targeted therapies as part of routine clinical care in NSCLC. Tissue biopsy is the criterion standard; however, genomic profiling of blood-derived circulating tumor...
8.
Liang W, Vergilio J, Salhia B, Huang H, Oki Y, Garrido-Laguna I, et al.
Oncologist
. 2018 Aug;
24(2):219-228.
PMID: 30108156
Background: The genomic landscape of Hodgkin lymphoma (HL) has been difficult to characterize due to the paucity of neoplastic cells and an abundant microenvironment. Such characterization is needed in order...
9.
Riess J, Gandara D, Frampton G, Madison R, Peled N, Bufill J, et al.
J Thorac Oncol
. 2018 Jul;
13(10):1560-1568.
PMID: 29981927
Introduction: EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations relatively insensitive to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). However, recent early clinical data suggests...
10.
Clark T, Chung J, Kennedy M, Hughes J, Chennagiri N, Lieber D, et al.
J Mol Diagn
. 2018 Jun;
20(5):686-702.
PMID: 29936259
Genomic profiling of circulating tumor DNA derived from cell-free DNA (cfDNA) in blood can provide a noninvasive method for detecting genomic biomarkers to guide clinical decision making for cancer patients....